Babu Yarlagadda S 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Feb 25, 2020
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-02-21+18,000→ 18,000 totalExercise: $11.13From: 2020-02-21Exp: 2024-12-22→ Common Stock (18,000 underlying)
Footnotes (1)
- [F1]On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.